H.C. Wainwright raised the firm’s price target on Monopar Therapeutics (MNPR) to $22 from $6 and keeps a Buy rating on the shares. The firm expects Monopar to be responsible for all global development, regulatory, and commercial efforts related to ALXN-1840. The analyst says the AstraZeneca licensing agreement is a major milestone and could transform the company from early-stage clinical development into a profitable commercial entity within 12 months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics reports Q3 EPS (37c), consensus (48c)
- Monopar Therapeutics Closes $19.2 Million Stock Offering
- Monopar Therapeutics 1.16M share Spot Secondary priced at $16.25
- Monopar Therapeutics announces common stock offering, no amount given
- Monopar Therapeutics Secures License for Wilson Disease Treatment